FREE SHIPPING ON ORDERS OVER $150

dihexa cancer hgf c-met agonist Anti-cancer therapeutic strategies based on HGF/MET, EpCAM, and tumor IS THERE A REAL RISK

$20.66

Quantity
- +
Description

This interaction is mediated by dual binding, with FHD mainly binding to the p53 TAD and FOXO4 CR3 binding to the p53 DNA-binding domain (DBD) 38 (Figure

dihexa cancer hgf c-met agonist Anti-cancer therapeutic strategies based on HGF/MET, EpCAM, and tumor IS THERE A REAL RISK

Jiang, L.-H., Shi, Y., Wang, L.-S

dihexa cancer hgf c-met agonist Anti-cancer therapeutic strategies based on HGF/MET, EpCAM, and tumor IS THERE A REAL RISK

First we discuss exocrine pancreatic disease, in which cobalamin does not absorb in body as intrinsic factor is not there to facilitate the absorption

dihexa cancer hgf c-met agonist Anti-cancer therapeutic strategies based on HGF/MET, EpCAM, and tumor IS THERE A REAL RISK

Saito, H

dihexa cancer hgf c-met agonist Anti-cancer therapeutic strategies based on HGF/MET, EpCAM, and tumor IS THERE A REAL RISK

You may also like

recommand products

Frontiers

US$ 27.24

Min. order: 1 piece

4.3 (23 reviews)

Sold : Login>>